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A new reactive-centre P1 residue mutation (444Arg~Ser), has been identified ina dysfunctional CI inhibitor protein, C1 inhibitor(Ba), contained 
in a type II hereditary angioedema pl sma. This substitution s compatible with a point mutation of the 444Arg codon (CGC~AGC), and repre- 
sents the first non-histidine, non-cysteine P 1residue mutant described for C 1 inhibitor. 
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1. INTRODUCTION 
C1 inhibitor, a member of the serine proteinase in- 
hibitor (serpin) superfamily, is active against pro- 
teinases of the complement (Clr, Cls), fibrinolytic 
(plasmin), coagulation (factor XIa, factor XIIa) and 
kinin-generation (kallikrein) systems [1-6]. Whilst C1 
inhibitor can inactivate other proteinases (e.g. the 7 
subunit of nerve growth factor [7] and tissue 
plasminogen activator [8]), the physiological 
significance of these interactions i unclear. The critical 
nature of C1 inhibitor in plasma proteinase regulation 
is highlighted by the disorder hereditary angioedema, 
which is inherited in an autosomal dominant manner 
[9,10]. Two forms of the disease occur, type I, in which 
the plasma level of both functional and antigenic C1 in- 
hibitor is low (5-30o70 of normal), and type II, where 
the antigenic level is normal but the functional level is 
greatly reduced [11]. This latter form is consequent on 
the synthesis and secretion of a dysfunctional C1 in- 
hibitor protein that is catabolized more slowly than the 
active protein [12,13]. 
Proteinase inhibitor members of the serpin family 
appear to use identical reaction mechanisms, and the 
inhibited proteinase forms a stable I:1 complex with 
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the inhibitor. This may be as an acyl-enzyme in- 
termediate, requiring the hydroxyl group of the pro- 
teinase active site serine residue and the newly-released 
carboxyl (of the P1 residue) of the serpin [14,15]. The 
specificity of inhibition is heavily influenced by the 
amino acid at the P1 position. The importance of this 
residue was demonstrated by a naturally-occurring mu- 
tant of another member of the serpin superfamily, 
Crl-antitrypsin Pittsburgh. This had a P1 methionine to 
arginine substitution, a d had lost its inhibitory activity 
against elastase (the natural substrate for 
~rl-antitrypsin), but had gained (lethal) inhibitory ac- 
tivity against hrombin [16]. That this effect was due 
solely to mutation of the P1 residue was confirmed by 
analysis of genetically-engineered cr~-antitrypsin 
mutants [17]. It was this demonstrable importance of 
the P1 residue that provided the initial impetus to 
search for similar mutations in the dysfunctional 
Cl-inhibitor proteins found in type II HAE plasmas. 
Recently, new analytical procedures [18] have allow- 
ed rapid analysis of Cl-inhibitor proteins from a large 
number of type II HAE plasmas, and these have shown 
a preponderance of mutations at the P 1 reactive centre 
residue (approximately 70°70 of the kindred studied) 
[19]. Furthermore, while random point mutation of the 
P1 arginine codon (CGC) potentially gives rise to 6 
possible products (Pro, Gly, Leu, Set, His and Cys), 
the observed mutations of this residue have, until now, 
been restricted either to histidine or to cysteine. This 
limited variability has been explained by the hyper- 
mutability of the CpG dinucleotide, generating CpA 
(hence CAC, histidine) or TpG (hence TGC, cysteine) 
dinucleotides [19,20]. 
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We here descr ibe the ident i f icat ion o f  the first non-  
hist id ine,  non-cyste ine P1 res idue mutant  o f  
C 1- inhibitor ,  a 444argin ine ,ser ine subst i tut ion in 
the dys funct iona l  prote in ,  C1 inhib i tor(Ba) .  This  
subst i tut ion  is compat ib le  with a po int  mutat ion  o f  the 
444arg in ine codon,  CGC ,AGC which,  whi le it 
results in loss o f  the CpG dinucleot ide,  is not  a result 
o f  deaminat ion  o f  5-methyl -cytos ine.  
2. MATERIALS  AND METHODS 
Normal plasma was drawn from healthy volunteers and made 
5 mM in benzamidine and EDTA. Plasma from the type II HAE pa- 
tient (Ba) was taken into EDTA only. Samples were th n stored at 
-70°C until required. Normal C1 inhibitor was purified using the 
method of Harrison [21]. 
Anti-C1 inhibitor IgG was prepared from a rabbit anti-Cl inhibitor 
antiserum as described previously [18], and coupled to Sepharose 
CL-4B using the procedure of March et al. [22]. 
2.1. Analysis of the C1 inhibitor proteins 
Plasma Cl-inhibitor was analysed as described by Aulak and Har- 
rison [18]. Briefly, 1 vol. of anti-C1 inhibitor-Sepharose CL-4B was 
incubated with 1 vol. plasma (in 10 mM EDTA, 10 mM ben- 
zamidine) and the Sepharose beads maintained in suspension during 
the incubation period (2 h at 4°C). The loaded beads were then wash- 
ed with PBS, PBS + 1 M NaCI, and again with PBS before digestion 
either with trypsin (bovine pancreatic; Tos-Phe-CH2CI treated; 
Sigma) or with Pseudomonas aeruginosa elastase (Ps.a.elastase; the 
kind gift of Dr Morihari, Kyoto Research Laboratories, Tokyo, 
Japan). Trypsin digestion was performed as follows: 25/~1 of the ad- 
sorbed resin was incubated with 20 ~1 trypsin (0.43/zM in 50 mM 
Tris/HCl, 100 mM NaCI, pH 8.0) for 40 min at 37°C, then digestion 
stopped by the addition of SDS-PAGE non-reducing sample prepara- 
tion buffer and heating for 2 min at 100°C. Ps.a.elastase digestion 
was performed using 350/A Sepharose beads onto which CI inhibitor 
had been adsorbed. After incubation with 5/zl Ps.a.elastase (3.0/~M 
in 50 mM Tris/HC1, 100 mM NaC1, 5 mM CaCI2, 50,~M ZnCI2, pH 
7.0) for 1 h at 37°C, the reaction was terminated by the addition of 
EDTA to a final concentration of 10 raM; 1 ml HPLC buffer (5o70 
acetonitrile, 0.1% TFA) was added and the mixture was left at 4°C 
for 20 min. This was then filtered through a 0.2/zm filter (Gelman 
Sciences) prior to peptide separation by reverse phase HPLC. 
Trypsin digestion of purified C1 inhibitor was as described by 
Aulak et al. [23], and Ps.a.elastase digestion of the purified protein 
as described by Pemberton et al. [24]. 
SDS-PAGE was performed using the buffer and sample prepara- 
tion systems of Laemmli [25] with a 10-20% polyacrylamide gradient 
gel. Molecular weight marker proteins were purchased from BDH. 
HPLC separation of Ps.a.elastase digested proteins was performed 
using a reversed phase polystyrene column (PLRP-S 300A; 
250 mm x 4.6 mm; Polymer Laboratories, Church Stretten, Shrop- 
shire, UK) and Waters HPLC instrumentation. After loading, the 
column was washed with 5% acetonitrile, 0.1% TFA for 10 min, 
then a linear gradient to 80% acetonitrile/0. I o70 TFA was developed 
over 40 min. Finally the column was washed for l0 min with 80°70 
acetonitrile/0.1% TFA before returning to the equilibration condi- 
tions. A flow rate of 1 ml/min was used throughout. 
Amino-terminal sequence analysis of the reactive centre peptide 
was performed by Dr L. Packman at the Protein Sequencing Facility 
of the Department of Biochemistry, University of Cambridge, Cam- 
bridge, UK, using Applied Biosystems instrumentation. 
3. RESULTS 
Fig. 1 shows SDS-PAGE analysis o f  the trypsin 
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Fig. 1. SDS-PAGE analysis of digestion of C1 inhibitor(Ba) with 
trypsin. Track 1, normal C1 inhibitor (15/~g). Track 2, normal CI 
inhibitor (15/zg) digested with trypsin. Track 3, C1 inhibitor derived 
from immunoadsorbed normal plasma. Track 4, CI inhibitor derived 
from immunoadsorbed normal plasma digested with trypsin. Track 
5, C 1 inhibitor derived from immunoadsorbed plasma from a type lI 
HAE patient (Ba kindred). Track 6, CI inhibitor derived from 
immunoadsorbed plasma from the type II HAE(Ba) patient and 
digested with trypsin. Molecular mass markers: 100 kDa, CI 
inhibitor; 85 kDa, major Ps.a.elastase cleavage fragment of CI 
inhibitor; 43 kDa, ovalbumin; 30 kDa, carbonic anhydrase; 17 kDa, 
myoglobin; 12 kDa, cytochrome c.
h ib i tor  immuno-adsorbed  f rom normal  p l sma,  and C1 
inh ib i tor  adsorbed f rom the var iant  (Ba) p lasma.  Both 
p lasmas conta in  normal -s i zed  (100 kDa)  C1 inh ib i tor  
( tracks 3 and 5). However ,  whi le the normal  p lasma 
gives an 85 kDa major  f ragment  after  t rypsin d igest ion 
(track 4), C1 inh ib i tor  f rom p lasma (Ba) gives a 97 kDa 
major  f ragment  (track 6), showing that  it has a P1 
res idue mutat ion .  
HPLC separat ion  o f  the Ps .a .e lastase digest ion pro-  
ducts  o f  the immunoadsorbed  C1 inhib i tor(Ba)  is 
shown in Fig. 2. The  major  f ragment  and react ive-  
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Ps.a.elastase Trypsin 
P7 P6 P5 P4 P3 P2 PI P'I P'2 P'3 P'4 
C1 -inhibitor Normal S A 1 S V A R T L L V 
TCC GCC ATC TCT GTG GCC CGC ACC CTG CTG GTC 
C1 -inhibitor(Ba) . . . . . . . . . . . . . . . . . .  A . . . . . . . . . . . . . .  
(S) V A S T L L V 
n n 
Ps.a.elastase Ps.a.elastase? 
Fig. 2. Chromatogram of HPLC resolution of the Ps.a.elastase 
digestion products of CI inhibitor(Ba). Digestion of C1 inhibitor 
adsorbed onto anti-Cl inhibitor with Ps.a.elastase and HPLC 
separation was as described in the text. 
centre containing carboxy-terminal peptides are well 
resolved from antibody-derived and C1 inhibitor 
amino-terminal peptides, eluting at 42 and 38 min, 
respectively. The 38 min peak was collected and sub- 
jected to amino-terminal sequence analysis. This show- 
ed two sequences, one generated from the cleavage 
between the P4 and P3 residues, and the second 
generated from the cleavage between the P1 and P ' I  
residues (Fig. 3). The first sequence is analogous to that 
seen in the reactive centre peptide released by 
Ps.a.elastase cleavage of the normal, P1 histidine, and 
P1 cysteine, inhibitors. The second sequence (-25% of 
the level of the first) could arise either as a consequence 
of cleaved C1 inhibitor being present in the starting 
material or as a consequence of generation of a new 
Ps.a.elastase cleavage site (444Ser-445Thr) by the new 
P1 residue. (While Fig. 1 appears to suggest that the 
former explanation is unlikely, a low level of a band 
similar in size to reactive centre cleaved C1 inhibitor 
was evident in the original gel.) These sequence data 
show unequivocally that C1 inhibitor(Ba) has a muta- 
tion of the P1 arginine residue to serine. 
4. DISCUSSION 
A number of C1 inhibitor proteins contained in type 
II HAE plasmas have now been characterised 
[18-20,23,26]. Many (about 70%) have P1 residue 
mutations, justifying our initial concentration on 
analysis of this residue. However, with the exception of 
the P1 serine mutant described in this paper, all have 
been either P1 cysteine or PI histidine mutants. The 
high preponderance of cysteine and histidine mutations 
has been explained by the nature of the P1 arginine 
codon [19,20]. This (CGC) contains aCG dinucleotide; 
methylation of the cytosine followed by deamination 
(to thymine) of the 5-methyl-cytosine thus generated 
leads to formation of TGC (cysteine; deamination of 
5-methyl-cytosine on the coding strand) or CAC 
(histidine; deamination on the non-coding strand 
followed by T-A base-pairing during DNA replication) 
codons. Interestingly, antithrombin III has a similar, 
high preponderance of P1 cysteine and P1 histidine 
variants [27-29], although a P1 Arg---,Pro mutation 
(antithrombin III Pescara) has recently been described 
[30]. As antithrombin III also has a P1 arginine ncod- 
ed by a CG dinucleotide-containing codon (CGT) [31], 
it seems likely that again it is the CG dinucleotide effect 
that is responsible for the observed frequency of P1 
residue mutations. C1 inhibitor(Ba) represents he first 
identification of a mutation of the P1 residue to 
anything other than histidine or cysteine in C1 in- 
hibitor. Furthermore, when considered together with 
antithrombin III (Pescara), it demonstrates that whilst 
the hyper-mutation f the CG dinucleotide is the pro- 
bable reason for the large number and limited diversity 
of PI residue mutations in 'argserpins' containing a CG 
dinucleotide in the P1 residue codon, other mutations 
of this residue can and do occur. 
Identification of this novel mutation is important for 
the following reason. While the P 1 residue is clearly a 
major determinant of inhibitor specificity, it does not 
have an over-riding influence. This is best illustrated 
with reference to the archetypal serpin, trrantitrypsin, 
which has a P1 methionine (and is the physiological in- 
hibitor of leukocyte lastase) rather than a P1 lysine or 
arginine residue, yet is still a highly effective inhibitor 
of trypsin [32]. One plausible xplanation for the non- 
identification of P 1 mutants other than histidine or cys- 
teine was that other mutations of this residue generated 
inhibitors that were still effective against the target en- 
zymes of C1 inhibitor, particularly those enzymes that 
were responsible for generation of the angioedema- 
causing peptide. Since the P1 serine mutation has been 
found in a typical type II HAE patient, C1 in- 
hibitor(Ba) must be effectively dysfunctional gainst 
the proteinase(s) responsible for the generation of the 
edema causing agent. 
The nature and mechanism of release of the agent(s) 
(bradykinin or a C2-derived peptide) responsible for 
edema formation is still controversial, with kallikrein, 
C 1 s and plasmin all being implicated in peptide release 
[33]. The clinical presentation of affected individuals 
indicates that C1 inhibitor(Ba) is inactive against he 
complement proteinases Cls and Clr. However, it is 
possible that it still retains activity against other plasma 
proteinases (or that it has acquired a novel activity). 
For example, while antitrypsin Pittsburg had lost in- 
hibitory activity against leukocyte lastase, it had gain- 
ed activity against hrombin [16]. Similarly, both CI 
inhibitor(At), a naturally-occurring P1 arginine to 
histidine mutant, and an engineered PI Arg , His C1 
inhibitor protein have significantly increased inhibitory 
activity against chymotrypsin ([34], Aulak, unpublish- 
ed data). We are therefore pursuing full kinetic analysis 
of C1 inhibitor(Ba) against a spectrum of plasma pro- 
teinases in the hope that this might give further insight 
into the possible molecular mechanism of HAE. 
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